Johnson & Johnson Posts Higher Quarterly Sales, Raises 2023 Outlook

Legal charges and Kenvue spinoff weigh on earnings

Johnson & Johnson is spinning off its consumer-health business into a company that will house well-known brands such as Tylenol. Photo: George Frey/Bloomberg News

Johnson & Johnson raised its full-year sales and earnings outlook after revenue rose 5.6% in the first quarter, lifted by demand for everything from Tylenol to the company’s pharmaceutical products and contact lenses.

The New Brunswick, N.J., healthcare-products company also said Tuesday that first-quarter earnings were largely wiped out by a $6.9 billion charge tied to J&J’s proposal to resolve tens of thousands of lawsuits alleging injuries caused by its talc-containing powders including Johnson’s Baby Powder.

What's News

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue reading your article with
a WSJ subscription

Subscribe Now

Already a subscriber? Sign In

Sponsored Offers
  • adidas:
    adidas Promo Code - Up to 50% Off 3-Stripe Favorites
  • Nike:
    Nike promo code: Members save up to 20% on select styles
  • American Eagle Outfitters:
    15% off American Eagle promo code
  • Personalization Mall:
    Personalization Mall Coupon: 25% off
  • 1-800-Flowers.com:
    Exclusive! 20% off 1800 Flowers promo code
  • Target:
    Target Promo Code: 20% off Entire Order